289 related articles for article (PubMed ID: 20055425)
1. Heat shock protein 90: inhibitors in clinical trials.
Biamonte MA; Van de Water R; Arndt JW; Scannevin RH; Perret D; Lee WC
J Med Chem; 2010 Jan; 53(1):3-17. PubMed ID: 20055425
[No Abstract] [Full Text] [Related]
2. Discovery of a macrocyclic o-aminobenzamide Hsp90 inhibitor with heterocyclic tether that shows extended biomarker activity and in vivo efficacy in a mouse xenograft model.
Zapf CW; Bloom JD; McBean JL; Dushin RG; Golas JM; Liu H; Lucas J; Boschelli F; Vogan E; Levin JI
Bioorg Med Chem Lett; 2011 Jun; 21(12):3627-31. PubMed ID: 21605975
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90.
Ge J; Normant E; Porter JR; Ali JA; Dembski MS; Gao Y; Georges AT; Grenier L; Pak RH; Patterson J; Sydor JR; Tibbitts TT; Tong JK; Adams J; Palombella VJ
J Med Chem; 2006 Jul; 49(15):4606-15. PubMed ID: 16854066
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and anticancer activity of geldanamycin derivatives derived from biosynthetically generated metabolites.
Lee K; Ryu JS; Jin Y; Kim W; Kaur N; Chung SJ; Jeon YJ; Park JT; Bang JS; Lee HS; Kim TY; Lee JJ; Hong YS
Org Biomol Chem; 2008 Jan; 6(2):340-8. PubMed ID: 18175003
[TBL] [Abstract][Full Text] [Related]
5. Purine-scaffold Hsp90 inhibitors.
Chiosis G; Tao H
IDrugs; 2006 Nov; 9(11):778-82. PubMed ID: 17096299
[TBL] [Abstract][Full Text] [Related]
6. Molecular characterization of macbecin as an Hsp90 inhibitor.
Martin CJ; Gaisser S; Challis IR; Carletti I; Wilkinson B; Gregory M; Prodromou C; Roe SM; Pearl LH; Boyd SM; Zhang MQ
J Med Chem; 2008 May; 51(9):2853-7. PubMed ID: 18357975
[TBL] [Abstract][Full Text] [Related]
7. Structure-based and in silico design of Hsp90 inhibitors.
Sgobba M; Rastelli G
ChemMedChem; 2009 Sep; 4(9):1399-409. PubMed ID: 19685544
[TBL] [Abstract][Full Text] [Related]
8. Optimizing natural products by biosynthetic engineering: discovery of nonquinone Hsp90 inhibitors.
Zhang MQ; Gaisser S; Nur-E-Alam M; Sheehan LS; Vousden WA; Gaitatzis N; Peck G; Coates NJ; Moss SJ; Radzom M; Foster TA; Sheridan RM; Gregory MA; Roe SM; Prodromou C; Pearl L; Boyd SM; Wilkinson B; Martin CJ
J Med Chem; 2008 Sep; 51(18):5494-7. PubMed ID: 18800759
[TBL] [Abstract][Full Text] [Related]
9. Total synthesis of resorcinol amide Hsp90 inhibitor AT13387.
Patel BH; Barrett AG
J Org Chem; 2012 Dec; 77(24):11296-301. PubMed ID: 23186098
[TBL] [Abstract][Full Text] [Related]
10. Total synthesis of herbimycin A.
Canova S; Bellosta V; Bigot A; Mailliet P; Mignani S; Cossy J
Org Lett; 2007 Jan; 9(1):145-8. PubMed ID: 17192106
[TBL] [Abstract][Full Text] [Related]
11. Potent triazolothione inhibitor of heat-shock protein-90.
Feldman RI; Mintzer B; Zhu D; Wu JM; Biroc SL; Yuan S; Emayan K; Chang Z; Chen D; Arnaiz DO; Bryant J; Ge XS; Whitlow M; Adler M; Polokoff MA; Li WW; Ferrer M; Sato T; Gu JM; Shen J; Tseng JL; Dinter H; Buckman B
Chem Biol Drug Des; 2009 Jul; 74(1):43-50. PubMed ID: 19519743
[TBL] [Abstract][Full Text] [Related]
12. Synthetic ansamycins prepared by a ring-expanding Claisen rearrangement. Synthesis and biological evaluation of ring and conformational analogues of the Hsp90 molecular chaperone inhibitor geldanamycin.
McErlean CS; Proisy N; Davis CJ; Boland NA; Sharp SY; Boxall K; Slawin AM; Workman P; Moody CJ
Org Biomol Chem; 2007 Feb; 5(3):531-46. PubMed ID: 17252137
[TBL] [Abstract][Full Text] [Related]
13. Discovery and development of heat shock protein 90 inhibitors as anticancer agents: a review of patented potent geldanamycin derivatives.
Kim T; Keum G; Pae AN
Expert Opin Ther Pat; 2013 Aug; 23(8):919-43. PubMed ID: 23641970
[TBL] [Abstract][Full Text] [Related]
14. Heat Shock Protein 90 Inhibitor Effects on Pancreatic Cancer Cell Cultures.
Gulla A; Kazlauskas E; Liang H; Strupas K; Petrauskas V; Matulis D; Eshleman JR
Pancreas; 2021 Apr; 50(4):625-632. PubMed ID: 33939678
[TBL] [Abstract][Full Text] [Related]
15. HSP-90 inhibitors promise to complement cancer therapies.
Vastag B
Nat Biotechnol; 2006 Nov; 24(11):1307. PubMed ID: 17093460
[No Abstract] [Full Text] [Related]
16. Potent cytotoxic C-11 modified geldanamycin analogues.
Tian ZQ; Wang Z; MacMillan KS; Zhou Y; Carreras CW; Mueller T; Myles DC; Liu Y
J Med Chem; 2009 May; 52(10):3265-73. PubMed ID: 19405528
[TBL] [Abstract][Full Text] [Related]
17. Hsp90 inhibitors: clinical development and future opportunities in oncology therapy.
Gao Z; Garcia-Echeverria C; Jensen MR
Curr Opin Drug Discov Devel; 2010 Mar; 13(2):193-202. PubMed ID: 20205053
[TBL] [Abstract][Full Text] [Related]
18. Redefining the Phenotype of Heat Shock Protein 90 (Hsp90) Inhibitors.
Wang Y; Koay YC; McAlpine SR
Chemistry; 2017 Feb; 23(9):2010-2013. PubMed ID: 27862436
[TBL] [Abstract][Full Text] [Related]
19. Rationally designed high-affinity 2-amino-6-halopurine heat shock protein 90 inhibitors that exhibit potent antitumor activity.
Kasibhatla SR; Hong K; Biamonte MA; Busch DJ; Karjian PL; Sensintaffar JL; Kamal A; Lough RE; Brekken J; Lundgren K; Grecko R; Timony GA; Ran Y; Mansfield R; Fritz LC; Ulm E; Burrows FJ; Boehm MF
J Med Chem; 2007 Jun; 50(12):2767-78. PubMed ID: 17488003
[TBL] [Abstract][Full Text] [Related]
20. Rational design and synthesis of ansa-adenosines as potential antitumor agents.
Muranaka K; Ichikawa S; Matsuda A
Nucleic Acids Symp Ser (Oxf); 2009; (53):5-6. PubMed ID: 19749232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
